2012 CHINET surveillance of bacterial resistance in China

Chinese Journal of Infection and Chemotherapy

Volumn 13, Issue 5, 2013, Pages 321-330

  Wang, Fu ^a   Zhu, Demei ^a   Hu, Fupin ^a   Jiang, Xiaofei ^a   Hu, Zhidong ^a   Li, Quan ^a   Sun, Ziyong ^a   Chen, Zhongju ^a   Xu, Yingchun ^a   Zhang, Xiao Jiang ^a   Wang, Chuanqing ^a   Wang, Aimin ^a   Ni, Yuxing ^a   Sun, Jingyong ^a   Chu, Yunzhuo ^a   Yu, Yunsong ^a   Lin, Jie ^a   Xu, Yuanhong ^a   Shen, Jilu ^a   Su, Danhong ^a   Zhuo, Cha ^a   Wei, Lianhua ^a   Wu, Ling ^a   Zhang, Zhaoxia ^a   Ji, Ping ^a   Zhang, Hong ^a   Kong, Jing ^a   Hu, Yunjian ^a   Ai, Xiaoman ^a   Shan, Bin ^a   Du, Yan ^a   more..

^a FUDAN UNIVERSITY   (China)

Author keywords

Antimicrobial susceptiblilty testing; Bacterial resistance; Carbapenem resistant enterobacteriaceae; Extended spectrum beta lactamase; Methicillin resistant staphylococcus; Multi drug resistant; Penicillin resistant streptococcus pneumoniae; Vancomycin resistant enterococcus

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; CARBAPENEM; COTRIMOXAZOLE; IMIPENEM; LINEZOLID; MEROPENEM; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PREVALENCE; PROTEUS MIRABILIS;

EID: 84929391897     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. CLSI Performance standards for antimicrobial susceptibility testing[S]. Twenty second Informational supplement Ml 00- S22 2012,32(3).
2. European Committee on Antimicrobial susceptibility testing, Breakpoint tables for interpretation of MICs and zone diameters[S]. Version 2, 2012, valid from 2012-01-01.
3. Bush K. Alarming β-blactamase-mediated resistance in multidrug-resistant Enterobacteraceae[J]. Curr Opinion Microbiol, 2010, 13(5): 558-564.
4. Nordmann P, Dortet L, Poirel L. Carbepenem resistance in Enterobacteriaceae: here is the storm! [J]. Trends Mol Med, 2012, 18(6); 263-271.
5. Hu FP, Chen SD, Xu XG, et al. Emergence of carhapenem resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China[J]. J Med Microbiol, 2012,61 (Ptl):132-136.
6. Yang Q, Wang H, Sun H, et al. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems; results from large hospital-based surveillance studies in China[J]. Antimicrob Agents Chemother, 2010, 54(5):573-577.
7. Chen SD, Hu FP, Xu XG, et al. High prevalence of KPC-2 carbapenemase coupled with CTX-M-type extended-spectrum (3-lactamase in carhapenem-resistant Klebsiella pneumoniae in a teaching hospital in China [J]. Antimicrob Agents Chemother, 2011, 55(5): 2493-2444.
8. Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant i- solates[J]. Antimicrob Agents Chemother, 2011, 55 (8): 3917-3921.
9. Lascols C, Peirano G, Hackel M, et al. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce Carbapenemase;first report of OXA-48-like enzymes in north America[J]. Antimicrob Agents Chemother, 2013, 57(1):130-136.
10. Porton A, Nordmann P, Poirel L. Characterization of OXA- 204, a carbapenem-hydrolyzing class D (3-lactamase from Klebsiella pneumoniae [J]. Antimicrob Agents Chemother, 2013, 57(1):633-636.
11. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase- producing Klebsiella pneumoniae in Brooklyn NY: molecular epidemiology and in vitro activity of polymyxin B and other a- gents[J]. J Antimicrob Chemother, 2005, 56(1): 128-132.
12. Elemam A, Rahimian J, Mandell W. Infection with panresis- tant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature [J]. Clin Infect Dis, 2009, 49 (2): 271-274.
13. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America[J]. Clin Inf Dis, 2009, 48(1); 1-12.
14. Wise R. The urgent need for new antibacterial agents[J]. J Antimicrob Chemotherapy, 2011, 66(9): 1939-1940.
15. Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political re- sponse[J]. J Antimicrob Chemother, 2012, 67(1): 1-3.
16. van Duin DV, Kaye RS, Neuner EA, et al. Carbapenem-re- sistant Enterobacteriaceaea review of treatment and out- comes[J]. Diagn Microbiol Infect Dis, 2013, 75(2); 115-120.
17. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes[J]. Future Microbiol, 2011, 6(6):653-666.
18. US FDA; FDA drug safety communication; increased risk of death with tygacil (Tigecycline) compared to other antibiotics used to treat similar infections. (2011-2012-2015).
19. Falagas ME, Kartoris AC, Kapaskelis AM, et al. Fosfomy- cin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systemic review [J]. Lancet Infect Dis, 2010, 10(1): 43-50.
20. Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline[j]. Int J Antimicrob Agents, 2011, 37(5): 415-419.